Print Page  |  Close Window

Overview

ChromaDex Corp. is an integrated, global nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to uncover the full potential of NAD and identify and develop novel, science-based ingredients. Its flagship ingredient, NIAGEN® nicotinamide riboside, sold directly to consumers as TRU NIAGEN®, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN® is helping the world AGE BETTER®

...
More »
Stock Quote
NASDAQ - CDXC
Price$3.47
Change (%) Stock is Up 0.27 (8.44%)
Volume212,138
Refresh quote
Real-Time Level 2 Quote
Recent NewsMore »
DateTitle 
01/23/19New Study Shows Supplementation with Nicotinamide Riboside (NR) During Breastfeeding Yields Measurable, Lasting Benefits to Mothers and Offspring in Animal Model
Landmark preclinical lactation study of unique form of vitamin B3 (nicotinamide riboside) showing remarkable results in rodents published in Cell Reports LOS ANGELES, Jan. 23, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) today reported that results of a first-of-a-kind preclinical study on lactation have shown that supplementation with the unique B3 vitamin nicotinamide riboside (NR, or Niagen) confers significant and enduring physiological benefits to mothers and offspring. Conduct... 
Printer Friendly Version
01/22/19ChromaDex Prepared to Proceed with Patent Infringement Action Against Elysium Health
ChromaDex to move forward with patent infringement action, following unsuccessful challenge by Elysium Health during Inter Partes Review (IPR) LOS ANGELES, Jan. 22, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) today reported the rejection of Elysium Health Inc.’s challenge to Claim 2 of U.S. Patent No. 8,383,086 ("the '086 patent") by the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office.  ChromaDex reported on January 22, 2018 that the PTAB denied Elysium... 
Printer Friendly Version
12/20/18ChromaDex Corp. and Nestlé Health Science Enter Global Commercial License and Supply Agreement for TRU NIAGEN®
ChromaDex Corporation and Nestlé Health Science agreement includes global commercial license and supply agreement for ingredient sales of TRU NIAGEN® for certain products within the medical nutrition and consumer health categories. LOS ANGELES, Dec. 20, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today it entered into a license and supply agreement with Nestlé Health Science (NHSc), a global leader pioneering quality science-based nutritional health solutions. The agreeme... 
Printer Friendly Version
What's New
DateTitle
12/05/18
December 2018 Investor Presentation PDF
12/04/18
ChromaDex Investor FAQs Third Quarter 2018 PDF
11/07/18
Q3 2018 Earnings Presentation PDF
11/07/18
2018 Q3 Quarterly Report on Form 10Q PDF
09/05/18
September 2018 Investor Presentation PDF
07/17/18
July 2018 Investor Presentation PDF
04/27/18
2018 Proxy Statement  PDF
03/15/18
2017 Annual Report on Form 10-K PDF
Get help downloading or viewing the above file types
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Chromadex Corp posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.